Foundation Awards Two $100,000 Grants to Advance Gastric Cancer Research
The Gastric Cancer Foundation is committed to addressing a key funding gap in research: Very little funding is available to early- and mid-stage career scientists who have novel ideas for treating gastric cancer. We are committed to filling this gap, in the hopes of advancing new breakthroughs for treating this tough cancer.

Therefore the Foundation is proud to announce it has awarded two new $100,000 research grants. The first will go to Eunyoung Choi, Ph.D., assistant professor in the section of surgical science at Vanderbilt University, who is focused on interrupting the transformation of precancerous stomach tissue into cancer. Choi’s research focuses on a population of cells discovered in her lab called dysplastic stem cells. Dysplasia is a precancerous condition of the stomach that has an 80% chance of progressing to gastric cancer. Choi’s study is designed to test whether it’s possible to inhibit the process by which dysplastic stem cells transform into cancer.

Specifically, Choi’s study will examine whether inhibiting an enzyme called SCD1 in mice with gastric dysplasia can prevent progression to cancer. Choi also plans to study SCD1 inhibition in human gastric pre-cancer cell models.

Seed funding for experiments that are focused on novel approaches is essential, Choi says, because it helps researchers generate the data they need to apply for larger grants from the National Institutes of Health (NIH). “With this one-year grant, we’ll be able to accomplish a lot,” she says. “This is a bridge to long-term funding.” She adds, “I love that this foundation is focused on gastric cancer. There are many patients suffering with this cancer in the world. I’m honored and excited to have this opportunity to help them.”

The second $100,000 grant will go to Nilay S. Sethi, M.D., Ph.D., associate program director of the medical oncology fellowship at Dana-Farber/Mass General Brigham and an assistant professor of medicine at Harvard medical school. Sethi is studying whether a popular class of breast, ovarian and prostate cancer drug could be useful in gastric cancer, too. Check out our next newsletter for further details about Sethi’s research. Learn more about our early-stage grant program here.
We are back in the Gesundheit Kitchen with Tips for Everyday Eating! Over the next few weeks, Foundation Board Member and "Chef Without a Stomach," Hans Rueffert will explore many ways to navigate around common digestion obstacles.

Let's start with breakfast - the first and often the hardest meal for patients. Chef Hans shares tips on how to start the day with fuel in your tank.
Research Roundup
Researchers are making inroads into discovering how gastric cancer forms and how it can best be treated based on tumor abnormalities:

Patients with ERBB2-positive gastric cancer do better on a first-line combination of chemotherapy, targeted therapy and immunotherapy than they do on a chemo-free regimen. That conclusion, published in Jama Oncology, was reached based on long progression-free survival and overall survival in a clinical trial.

Imugene Limited announced that in a phase 2 trial of its immunotherapy drug, HER-Vaxx, in Her-2/Neu overexpressing gastric cancer, there was a 41.5% survival benefit in patients taking the drug with chemotherapy over those on chemotherapy alone.

A research team at Vanderbilt University identified a specific type of stem cell that can evolve into multiple types of stomach cancers. They also discovered that pyrvinium, a commonly used medicine to treat pinworms, blocked the regeneration of these cells by controlling a specific signaling protein.
Quick Links to Resources
Special Thanks to Our
National Sustaining Sponsors
Spread the word. Share the Gastric Cancer Foundation Newsletter.